Organon & Co. — Director's Dealing 2023

Apr 4, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Organon & Co. (OGN)
CIK: 0001821825
Period of Report: 2023-03-31

Reporting Person: WALSH MATTHEW M (Chief Financial Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2023-03-31	Common Stock	M	7753	$0.00	Acquired	39459	Direct
2023-03-31	Common Stock	F	2656	$23.09	Disposed	36803	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2023-03-31	Restricted Stock Units	$	M	7753	Disposed		Common Stock (7753)	Direct
2023-03-31	Restricted Stock Units	$	A	36139	Acquired	2026-03-31	Common Stock (36139)	Direct
2023-03-31	Stock Option (right to buy)	$23.52	A	129770	Acquired	2033-03-31	Common Stock (129770)	Direct

Footnotes

F1: Each Restricted Stock Unit converts into one share of Organon & Co. ("Organon") common stock.

F2: On March 31, 2023, one-third of the RSUs vested with the remaining RSUs to vest in two equal installments on March 31, 2024 and March 31, 2025.

F3: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon common stock for each RSU.

F4: These RSUs vest and are distributed as shares of Organon common stock in three equal installments on March 31, 2024, March 31, 2025 and March 31, 2026.

F5: The Reporting Person was granted stock options, which vest and become exercisable in three equal installments on March 31, 2024, March 31, 2025 and March 31, 2026.